Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics' stock price has been significantly impacted by regulatory developments concerning Anaphylm™. On January 9, 2026, the FDA identified deficiencies in the NDA for Anaphylm™, leading to a substantial drop in AQST shares. In March 2026, Aquestive completed a Type A meeting with the FDA regarding the resubmission of the Anaphylm™ NDA and reaffirmed its guidance to resubmit the Anaphylm™ NDA in the third quarter of 2026. In April 2026, a securities fraud class-action lawsuit was filed against Aquestive Therapeutics. Despite these setbacks, the stock has seen some recovery, with a 41.13% increase over the past six months as of May 2026.

There is an indication of demand seasonality for Aquestive Therapeutics' products, specifically for Anaphylm™, its epinephrine sublingual film for severe allergic reactions. Commercialization efforts for Anaphylm™ are expected to ramp up in the first quarter of 2026, ahead of the "peak spring allergy season."

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative orally administered therapies. The company utilizes its PharmFilm® technology to create dissolvable films for drug delivery. Its commercial product portfolio includes Sympazan®, Exservan™, Suboxone®, Ondif®, Emylif, Zuplenz, Kynmobi™, and Azstarys®. The company's pipeline includes Anaphylm™ (AQST-109), Libervant® Buccal Film, AQST-108, and AQST-305.

Aquestive Therapeutics is headquartered in Warren, New Jersey, United States, with the majority of its revenue generated from the United States. The company aims for global expansion through strategic partnerships and licensing agreements, with its commercialized products marketed internationally by its licensees.

Aquestive Therapeutics' brand reputation has been primarily influenced by the regulatory journey of Anaphylm™. The FDA's identification of deficiencies in the Anaphylm™ NDA negatively impacted the company's reputation and stock price. The company's proactive engagement with the FDA indicates efforts to address the issues and restore confidence. Analysts generally maintain a "Buy" rating, implying a belief in the underlying value of Aquestive's technology and product pipeline.

Aquestive Therapeutics has a mixed ownership structure comprising institutional, insider, and retail investors. Approximately 59.15% of the company's stock is held by institutional shareholders, including Bratton Capital Management, L.P., BlackRock, Inc., and RTW Investments, LP. Retail investors collectively hold a significant portion, estimated at 34.20% to 77.90% of the shares. Insiders hold approximately 2.89% to 6.65% of the company's stock.